USA USA: 1-631-626-9181 Europe Europe: 44-207-097-1828  

Tissue samples, tissue arrays, cells, microorganisms, probes and services for your research.

Web Search    Google
Featured Services
Ordering Information

Payment methods we support:
✭ Invoice / Purchase Order
✭ Credit card

Alzheimer's Disease Modeling and Assays


Alzheimer's disease (AD) is the most common form of neurodegenerative disease, characterized by two aberrant features, the amyloid plaques and the neurofibrillary tangles. The initial pathophysiologic changes of AD are found in the hippocampus region of the brain, disrupting memory and the ability to learn. AD progression is linked to nerve cell dysfunction and cell death due to the accumulation of two protein aggregates: β-amyloid (Aβ) and tau. This cognitive and memory decline age-related disease causes suffering to the patient and their caregivers. Getting treatment or prevention of AD has attracted extensive attention worldwide. As a result, scientists are putting great efforts in understanding the mechanisms underlying the development of the disease as well as treatment for the disease.

The well-known neuropathogenic hallmarks of AD consist of aggregated amyloid beta (Aβ) and abnormal neurites. It is demonstrated that a dysregulated proteolytic processing of its precursor molecule, the Amyloid Precursor Protein (APP), can cause the accumulation of Aβ. Aβ can also cause caspases-mediated tau cleavage and hyperphosphorylation by activating specific kinases, thus promoting its aggregation, mis-localization and accumulation with consequent neurofibrillary tangles formation. On the other hand, Tau is a neuron specific microtubule-associated protein that regulates microtubule stability, tau dissociates from microtubules and forms insoluble aggregates called neurofibrillary tangles (NFTs). Both total tau (t-tau) and phosphorylated tau (p-tau) proteins are measured and associated with AD. Thus, Aβ peptide and tau exert crucial roles in neuronal loss or dysfunction, which would cause the increased reactive oxygen species (ROS) production, membrane damage, altered mitochondrial metabolism, abortive cell cycle events, and DNA damage/repair and inflammatory processes inevitably leading to neuronal dysfunction. Based on the above understanding, an appropriate in vitro model is deeply needed to mimic the pathogenesis and progression of AD, which could also work better with assays to study the drug candidates for Alzheimer's disease.

With extensive experience and state-of-the-art technologies, Creative Bioarray is offering Alzheimer's diseases modeling and assays to help our customers open the door for generating new insight into disease pathophysiology and improving the process of drug development.


  • Various cell types (both cell lines and primary neuronal cultures; human cells or other species) are available for building Alzheimer's disease models according to your application.
  • Our neurotoxicity assay, neuroprotective effect assay, and neurite outgrowth assay can cover most aspects for evaluation of new drugs.
  • Customized assays and High-throughput screening are available.
  • The final report will include the protocol of disease modeling and image analysis as well as statistical analysis.

Disease Modeling and assays available

Creative Bioarray offers development of custom designed in vitro models by using primary neuronal cultures, cell lines, iPS cells with genetic modifications, which are phenotypically closer to the adult neuronal network and mimic the development of AD. Our custom model services focus on but not restricted to AD induced by the accumulation and aggregation of Aβ. We also offer a wide range of assays that enable more accurate prediction of patient response to pharmacotherapy:

  • General neural toxicity assay
  • Amyloid β (Aβ) peptide aggregation inhibition assay
  • Aβ induced neurotoxicity assay
  • Tau aggregation assay
  • Neurite outgrowth assay

We provide this powerful and versatile tool for AD therapy as well as basic research to help our customers understand more about the underlying mechanisms in the progression of AD.

Study Example

Neurite outgrowth is inhibited by (intracellular) amyloid and tau treatment, and rescued by β-secretase inhibitor and methylene blue respectively.Figure 1. Neurite outgrowth is inhibited by (intracellular) amyloid and tau treatment, and rescued by β-secretase inhibitor and methylene blue respectively.

Quotation and ordering

Call us today at 631-626-9181 or email us at for a quotation. Contact us if you have any questions. Our customer service representatives are available 24hr a day!


  1. Nordin, N., et al. An overview of in vitro research models for Alzheimer's disease (AD). Pathogenesis. 17.1: 18-28.
  2. Calissano, P., et al. Apoptosis and in vitro Alzheimer's disease neuronal models. Communicative & integrative biology. 2009, 2.2: 163-169.
  3. Stoppelkamp, S., et al. In vitro modelling of Alzheimer's disease: degeneration and cell death induced by viral delivery of amyloid and tau. Experimental neurology. 2011, 229.2: 226-237.

Related Sections


Neurological Disorder:

Customer Support & Price Inquiry
Please input "bioarray" as verification code.
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-626-9181
Fax: 1-631-614-7828

Tel: 44-207-097-1828